Success Metrics

Completion Rate
0%(0/1)
Active Trials
2(50%)
Terminated
1(25%)

Phase Distribution

Ph phase_2
1
25%
Ph phase_4
1
25%
Ph phase_3
2
50%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Terminated(2)

Detailed Status

Recruiting2
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
0.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 32 (50.0%)
Phase 41 (25.0%)

Trials by Status

recruiting250%
terminated125%
withdrawn125%

Recent Activity

2 active trials
Showing 4 of 4
recruitingphase_3

Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)

NCT07094087
recruitingphase_2

Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery

NCT07032792
terminatedphase_3

Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study)

NCT04589949
withdrawnphase_4

PCC and Fibrinogen Compared With FFP in PPH

NCT01910675

Clinical Trials (4)

Showing 4 of 4 trials
NCT07094087Phase 3

Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)

Recruiting
NCT07032792Phase 2

Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery

Recruiting
NCT04589949Phase 3

Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study)

Terminated
NCT01910675Phase 4

PCC and Fibrinogen Compared With FFP in PPH

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4